Supernus is executing a strategic investment phase, evidenced by a 32.4% YoY revenue surge in 2026Q2 to $219.1M, yet this growth is accompanied by a sharp SG&A escalation to $133.6M, driving an operating loss of -$58.0M. The company maintains a conservative ba...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $0.54+27.8% vs $0.42 | $219M+6.7% vs $205M |
Q2 2026 May 5, 2026 | $0.59+110.7% vs $0.28 | $208M+7.7% vs $193M |
Q1 2026 Feb 24, 2026 | $0.92+228.6% vs $0.28 | $212M+8.4% vs $195M |
Q4 2025 Nov 4, 2025 | $1.01+23.2% vs $0.82 | $192M-1.3% vs $195M |
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation con.
Benchmark SUPN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Supernus Pharmaceuticals, Inc. (SUPN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $43.75 | $2.54B | -64.34 | 8.63% | -5.36% | -3.68% | — | |
| $24.70 | $971.57M | 154.38 | 3.63% | 1.96% | 2.13% | — | |
| $26.41 | $4.52B | 11.53 | 11.87% | 33.42% | 32.39% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — | |
| $14.31 | $1.98B | -1.39 | -2.75% | -41.85% | -55.97% | — | |
| $100.00 | $6.51B | 29.33 | 0.5% | 17.69% | 23.27% | — |
Supernus Pharmaceuticals, Inc. (SUPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Supernus Pharmaceuticals, Inc. (SUPN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Aug 3, 2026·SEC
Aug 3, 2026·SEC
Get notified when SUPN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Supernus Pharmaceuticals, Inc. (SUPN) stock FAQ — growth, dividends, profitability & financials explained
Supernus Pharmaceuticals, Inc. (SUPN) reported $830.4M in revenue for fiscal year 2025. This represents a 9242% increase from $8.9M in 2008.
Supernus Pharmaceuticals, Inc. (SUPN) grew revenue by 8.6% over the past year. This is steady growth.
Supernus Pharmaceuticals, Inc. (SUPN) reported a net loss of $109.9M for fiscal year 2025.
Supernus Pharmaceuticals, Inc. (SUPN) has a return on equity (ROE) of -3.7%. Negative ROE indicates the company is unprofitable.
Supernus Pharmaceuticals, Inc. (SUPN) generated $18.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
